Lipid-related residual risk and renal function for occurrence and prognosis among patients with first-event acute coronary syndrome and normal LDL cholesterol

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Chien, Kuo Liong ^a,b   Lin, Hung Ju ^b   Hsu, Hsiu Ching ^b   Chen, Ming Fong ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

acute coronary syndrome; dyslipidemia; residual risk

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY RISK; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LIPID RELATED RESIDUAL RISK; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; KIDNEY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR;

ACUTE CORONARY SYNDROME; AGED; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES;

EID: 81255178595     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-215     Document Type: Article

References (39)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 106 25 3143 3421 12485966
2. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, et al. Eur Heart J 2007 28 19 2375 2414 17726041
3. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, et al. Circulation 2007 115 1 114 126 17192512 (Pubitemid 46058619)
4. Standards of medical care in diabetes - 2008. Diabetes Care 2008 31 Suppl 1 12 54 18165335
5. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, et al. Lancet 2005 366 9493 1267 1278 16214597
6. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C, Lancet 2008 371 9607 117 125 10.1016/S0140-6736(08)60104-X 18191683
7. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, N Engl J Med 2004 350 15 1495 1504 10.1056/NEJMoa040583 15007110 (Pubitemid 38477774)
8. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, et al. N Engl J Med 2005 352 14 1425 1435 10.1056/NEJMoa050461 15755765 (Pubitemid 40471450)
9. Contribution of High Plasma Triglycerides and Low High-Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control. Carey VJ, Bishop L, Laranjo N, Harshfield BJ, Kwiat C, Sacks FM, The American Journal of Cardiology 2010 106 6 757 763 10.1016/j.amjcard.2010.05.002 20816113
10. Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i). Fruchart JC, Sacks FM, Hermans MP, Curr Med Res Opin 2010 26 8 1793 1797 10.1185/03007995.2010.489341 20482323
11. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, Chiang PH, Hsu CC, Sung PK, Hsu YH, et al. Lancet 2008 371 9631 2173 2182 10.1016/S0140-6736(08)60952-6 18586172 (Pubitemid 351890412)
12. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ, J Am Soc Nephrol 2004 15 5 1307 1315 10.1097/01.ASN.0000123691.46138. E2 15100371 (Pubitemid 38526012)
13. Renal function and metabolic syndrome components on cardiovascular and all-cause mortality. Chien KL, Hsu HC, Lee YT, Chen MF, Atherosclerosis 2008 197 2 860 867 10.1016/j.atherosclerosis.2007.07.037 17854811 (Pubitemid 351444792)
14. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR, Am J Med 1977 62 5 707 714 10.1016/0002-9343(77)90874-9 193398 (Pubitemid 8110784)
15. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Assmann G, Cullen P, Schulte H, Circulation 2002 105 3 310 315 10.1161/hc0302.102575 11804985 (Pubitemid 34106178)
16. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136, 905 hospitalizations in Get With The Guidelines. Sachdeva A, Cannon CP, Deedwania PC, Labresh KA, Smith SC Jr, Dai D, Hernandez A, Fonarow GC, Am Heart J 2009 157 1 111 117 e112 10.1016/j.ahj.2008.08.010 19081406
17. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, et al. Lancet 2004 364 9438 937 952 10.1016/S0140-6736(04)17018-9 15364185 (Pubitemid 39208455)
18. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH, Am J Cardiol 2007 100 10 1499 1501 10.1016/j.amjcard.2007.06.058 17996508 (Pubitemid 350050854)
19. Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V, Circulation 2007 115 4 450 458 10.1161/CIRCULATIONAHA.106. 637793 17190864 (Pubitemid 46184196)
20. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM, JAMA 2007 298 3 309 316 10.1001/jama.298.3.309 17635891 (Pubitemid 47080485)
21. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A, JAMA 2007 298 3 299 308 10.1001/jama.298.3.299 17635890 (Pubitemid 47080484)
22. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Assmann G, Schulte H, Am J Cardiol 1992 70 7 733 737 10.1016/0002-9149(92)90550-I 1519522
23. High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Weverling-Rijnsburger AW, Jonkers IJ, van Exel E, Gussekloo J, Westendorp RG, Arch Intern Med 2003 163 13 1549 1554 10.1001/archinte.163.13.1549 12860577 (Pubitemid 36835099)
24. Risk factor paradox in wasting diseases. Kalantar-Zadeh K, Horwich TB, Oreopoulos A, Kovesdy CP, Younessi H, Anker SD, Morley JE, Current Opinion in Clinical Nutrition & Metabolic Care 2007 10 4 433 442 410.1097/MCO. 1090b1013e3281a30594 10.1097/MCO.0b013e3281a30594 21884288 (Pubitemid 46934112)
25. Obesity and heart failure prognosis: paradox or reverse epidemiology? Lavie CJ, Mehra MR, Milani RV, European Heart Journal 2005 26 1 5 7 15615792 (Pubitemid 40221116)
26. Reverse Epidemiology, Obesity and Mortality in Chronic Kidney Disease: Modelling Mortality Expectations Using Energetics. Speakman JR, Westerterp KR, Blood Purification 2010 29 2 150 157 10.1159/000245642 20093821
27. The Body Mass Index Paradox and an Obesity, Inflammation, and Atherosclerosis Syndrome in Chronic Kidney Disease. Beddhu S, Seminars in Dialysis 2004 17 3 229 232 10.1111/j.0894-0959.2004.17311.x 15144550 (Pubitemid 38824505)
28. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D, Kidney Int 1999 56 6 2214 2219 10.1046/j.1523-1755.1999.00773.x 10594797 (Pubitemid 30004750)
29. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA, Kuller LH, Newman AB, J Am Coll Cardiol 2003 41 8 1364 1372 10.1016/S0735-1097(03)00163-3 12706933 (Pubitemid 36438998)
30. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Garg AX, Clark WF, Haynes RB, House AA, Kidney Int 2002 61 4 1486 1494 10.1046/j.1523-1755.2002.00270.x 11918756 (Pubitemid 34304510)
31. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY, N Engl J Med 2004 351 13 1296 1305 10.1056/NEJMoa041031 15385656 (Pubitemid 39268908)
32. Predictive Variables for Mortality After Acute Ischemic Stroke. Carter AM, Catto AJ, Mansfield MW, Bamford JM, Grant PJ, Stroke 2007 38 6 1873 1880 10.1161/STROKEAHA.106.474569 17446429 (Pubitemid 46847262)
33. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Fruchart JC, Sacks FM, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, et al. Diab Vasc Dis Res 2008 5 4 319 335 10.3132/dvdr.2008.046 18958843
34. Consistency in genetic inheritance mode and heritability patterns of triglyceride vs. high density lipoprotein cholesterol ratio in two Taiwanese family samples. Chien KL, Hsu HC, Su TC, Lee YT, BMC Journal, Genetics 2003 4 7 16
35. Cholesterol determination in high-density lipoproteins separated by three different methods. Lopes-Virella M, Stone P, Ellis S, Colwell JA, ClinChem 1977 23 5 882 884 (Pubitemid 8088312)
36. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, Ann Intern Med 1999 130 6 461 470 10075613 (Pubitemid 29135798)
37. The multiple logistic regression model. Hosmer DW Jr, Lemeshow S, Applied logistic regression New York: John Wiley & Sons 1 1989 25 37
38. Applied survival analysis: regression modeling of time to event data. Hosmer DW, Lemeshow S, New York: Wiley 1999
39. Flexible regression models with cubic splines. Durrleman S, Simon R, Stat Med 1989 8 5 551 561 10.1002/sim.4780080504 2657958 (Pubitemid 19116001)